Superworth

Cooper Companies COO

Medical - Instruments & Supplies, Healthcare
$61.21
−0.71%
Market cap
$11.6B
PE
20.9×
10y median 40.2×
Forward PE
n/m
not a meaningful number
Price to sales
2.7×
EV/EBIT
17.2×
Revenue, 12 months
$4.2B
+5% on a year ago
Net margin
13.5%
Free cash flow yield
5.8%

Cooper Companies trades at 20.9× trailing earnings, cheaper than 94% of the last ten years. Revenue was $4.2B over the last twelve months, up 5% on a year earlier with a 13% net margin.

Charts

Financials

Income statement for COO, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$927.1M+9%$931.6M+9%$942.6M+7%$1B+8%$1B+10%$964.7M+4%$1B+6%$1.1B+6%$1.1B+5%$1B+6%$1.1B+8%$1.1B+1%
Cost of revenue$320.6M+3%$307.8M+3%$311.4M+6%$339.8M+6%$340.7M+6%$304.5M−1%$323.2M+4%$368.3M+8%$414.3M+22%$328.9M+8%$346.1M+7%$354.3M−4%
Gross profit$606.5M+13%$623.8M+12%$631.2M+8%$663M+9%$677.7M+12%$660.2M+6%$679.1M+8%$692M+4%$650.8M−4%$695.2M+5%$735.4M+8%$711.9M+3%
R&D$36.7M+26%$39.5M+25%$38.9M+19%$39M+7%$37.7M+3%$40.7M+3%$45.5M+17%$44.6M+14%$41.4M+10%$44.3M+9%$42.5M−7%$41.6M−7%
SG&A$387.6M+8%$380.9M+15%$380.3M−7%$381.1M+2%$391.4M+1%$387.9M+2%$399M+5%$421.7M+11%$419.2M+7%$390.2M+1%$676.2M+70%$401.3M−5%
$135.7M+31%$153.1M+2%$161.7M+68%$192.5M+27%$198.4M+46%$182M+19%$184.8M+14%$175.7M−9%$140.4M−29%$212.8M+17%−$31M$222M+26%
Interest expense$26.3M+15%$29.9M+15%$28.9M+11%$28.5M+6%$27M+3%$26M−13%$24.2M−16%$25.4M−11%$24.4M−10%$22.4M−14%$20.9M−14%$21.5M−15%
Pre-tax income$106.4M+47%$120M−2%$130M+98%$163.7M+38%$168.6M+59%$153.3M+28%$144.5M+11%$151.9M−7%$116.8M−31%$192.2M+25%−$48.4M$201.8M+33%
$21.9M+222%$38.8M+4%$41.1M+59%$59M+76%$51.1M+133%$49M+26%$56.8M+38%$53.6M−9%$32.2M−37%$61.4M+25%$29.5M−48%−$231M
Net income$84.5M+29%$81.2M−4%$88.9M+123%$104.7M+23%$117.5M+39%$104.3M+28%$87.7M−1%$98.3M−6%$84.6M−28%$130.8M+25%−$77.9M$432.8M+340%
$0.42+27%$0.41−5%$0.44+120%$0.52+21%$0.59+41%$0.52+27%$0.44+0%$0.49−6%$0.43−27%$0.66+27%−$0.40$2.24+357%
199.6M+0%199.9M+1%200.5M+1%200.6M+1%200.7M+1%201.2M+1%200.7M+0%200M−0%198.2M−1%196.7M−2%195M−3%193.4M−3%

EPS, diluted: 9 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 17 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest Cooper Companies' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
COOCooper Companies$11.6B20.9×40.2×n/m2.7×+5%13.5%
ALGNAlign Technology$11B26.9×43.3×n/m2.7×+4%10.0%
GMEDGlobus Medical$10.9B20.8×37.4×n/m3.5×+20%17.0%
PENPenumbra$12.8B79.7×197×n/m8.5×+18%10.7%
PODDInsulet$10.3B27.9×63.0×n/m3.4×+29%12.3%
SOLVSolventum$14.5B10.4×10.7×n/m1.7×−1%17.3%
MSAMSA Safety$7B22.7×36.3×n/m3.6×+6%16.1%
MMSIMerit Medical Systems$5.6B38.6×57.5×n/m3.5×+10%9.2%
HAEHaemonetics$5.4B58.1×51.6×n/m4.0×+0%7.1%
WSTWest Pharmaceutical Services$27.6B50.2×45.8×42.2×8.3×+12%17.0%
VNTVontier$4.6B14.3×13.5×n/m1.5×+1%11.3%
Peer median$10.6B27.4×44.6×42.2×3.5×+8%11.8%

Investors who own it

Investors we follow who held Cooper Companies at the end of Jun 30, 2026, from their 13F filings.

More on Cooper Companies

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .